BPC-157: Mechanism of Action and Preclinical Evidence

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. Since its initial characterisation in the 1990s, it has been the subject of extensive preclinical research, with studies investigating its effects on wound healing, tissue repair, angiogenesis, and cytoprotection across multiple organ systems.

Molecular Background

BPC-157 consists of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) and is stable in human gastric juice — an unusual property for a peptide. This stability distinguishes it from many other bioactive peptides that are rapidly degraded in the gastrointestinal tract.

Sikiric et al. (2018), in a comprehensive review published in Current Pharmaceutical Design, catalogued the extensive preclinical evidence for BPC-157, covering studies in wound healing, tendon and ligament repair, bone healing, gastrointestinal protection, and neuroprotection.

Proposed Mechanisms of Action

The precise molecular mechanism of BPC-157 remains under investigation, but several pathways have been implicated in preclinical studies:

• Upregulation of growth factor expression (VEGF, EGF, and their receptors)
• Promotion of angiogenesis — formation of new blood vessels at injury sites
• Modulation of the nitric oxide (NO) system
• Interaction with the dopaminergic system
• Anti-inflammatory effects via modulation of cytokine profiles
• Promotion of tendon and ligament fibroblast growth and migration

Chang et al. (2011), writing in the Journal of Pharmacological Sciences, demonstrated that BPC-157 accelerated tendon healing in a rat model by promoting tendon fibroblast proliferation and migration, with evidence of enhanced collagen organisation at the repair site.

Gastrointestinal Effects

BPC-157 has shown consistent gastroprotective effects in preclinical models. Studies have demonstrated protection against NSAID-induced gastric lesions, ethanol-induced damage, and various forms of experimentally induced colitis. Sikiric et al. (2014) reported that BPC-157 maintained gastrointestinal mucosal integrity across multiple challenge models.

Current Limitations

It is important to note that the evidence for BPC-157 remains almost entirely preclinical. As of early 2026, no large-scale, randomised, controlled human clinical trials have been published. The available preclinical data, while extensive and consistent, cannot be directly extrapolated to human clinical outcomes without appropriate clinical validation.

Additionally, the regulatory status of BPC-157 varies by jurisdiction. In many markets, it is classified as a research compound and is not approved for therapeutic use. Healthcare professionals considering BPC-157 should be aware of the regulatory framework in their jurisdiction.